Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glepaglutide - Zealand Pharma

Drug Profile

Glepaglutide - Zealand Pharma

Alternative Names: ZP 1848

Latest Information Update: 17 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Class Anti-inflammatories; Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Short bowel syndrome
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 07 May 2019 Phase-III clinical trials in Short bowel syndrome (In adults, In the elderly) in Poland, United Kingdom (SC) (NCT03905707) (EudraCT2018-001429-26)
  • 05 Apr 2019 Zealand Pharma plans a phase III trial for Short bowel syndrome in the US, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Poland and United Kingdom (SC, Injection) (NCT03905707)
  • 20 Oct 2018 Pharmacodynamics data from preclinical trials in Short bowel syndrome presented at the 26th United European Gastroenterology Week (UEGW- 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top